RxDoctor Payments Data

Phillip Toth

Internal Medicine · Indianapolis, INNPI 1891098034

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (59.4%), food and beverage and education — rather than concentrated in one kind of arrangement. Novo Nordisk AS accounts for 88.2% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $592 and has fallen 89.1% since, to $65 in 2025.

$671in general payments, 2019–2025

Across 6 payments — averaging $111.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$592
  • Novo Nordisk$65
  • Echosens North America, Inc.$14
$3,218,985in research payments, 2019–2025

Across 1,275 payments — averaging $2524.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$1.5M
  • AstraZeneca$784K
  • Eli Lilly$520K
  • Pfizer$218K
  • Novartis$186K
  • Akcea Therapeutics, Inc.$27K
  • plus $16K from 4 others

What the payments were for

  • Travel & lodging$39959%
  • Food & beverage$20831%
  • Education$6510%

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$671 in reported general payments places this provider in the 70th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Other internal medicine in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →